Cortical neurogenesis follows a simple lineage: apical radial glia cells (RGCs) generate basal progenitors, and these produce neurons. How this occurs in species with expanded germinal zones and a folded cortex, such as human, remains unclear. We used single-cell RNA sequencing from individual cortical germinal zones in ferret and barcoded lineage tracking to determine the molecular diversity of progenitor cells and their lineages. We identified multiple RGC classes that initiate parallel lineages, converging onto a common class of newborn neuron. Parallel RGC classes and transcriptomic trajectories were repeated across germinal zones and conserved in ferret and human, but not in mouse. Neurons followed parallel differentiation trajectories in the gyrus and sulcus, with different expressions of human cortical malformation genes. Progenitor cell lineage multiplicity is conserved in the folded mammalian cerebral cortex.
The ETS domain family of transcription factors is involved in a number of biological processes, and is commonly misregulated in various forms of cancer. Using microarray datasets from patients with different grades of glioma, we have analyzed the expression profiles of various ETS genes, and have identified ETV1, ELK3, ETV4, ELF4, and ETV6 as novel biomarkers for the identification of different glioma grades. We have further analyzed the gene regulatory networks of ETS transcription factors and compared them to previous microarray studies, where Elk-1-VP16 or PEA3-VP16 were overexpressed in neuroblastoma cell lines, and we identify unique and common regulatory networks for these ETS proteins.
1 May 2022 in OMICS: A Journal of Integrative Biology
Multiple sclerosis (MS) is a demyelinating disorder that affects multiple regions of the central nervous system such as the brain, spinal cord, and optic nerves. Susceptibility to MS, as well as disease progression rates, displays marked patient-to-patient variability. To date, biomarkers that forecast differences in clinical phenotypes and outcomes have been limited. In this context, cell-type-specific interactome analyses offer important prospects and hope for novel diagnostics and therapeutics. We report here an original study using bioinformatic analysis of MS data sets that revealed interaction profiles as well as specific hub proteins in white matter (WM) and gray matter (GM) that appear critical for disease mechanisms. First, cell-type-specific interactome analyses suggested that while interactions within the WM were focused on oligodendrocytes, interactions within the GM were mostly neuron centric. Second, hub proteins such as APP, EGLN3, PTEN, and LRRK2 were identified to be differentially regulated in MS data sets. Lastly, a comparison of the brain and peripheral blood samples identified biomarker candidates such as NRGN, CRTC1, CDC42, and IFITM3 to be differentially expressed in different types of MS. These findings offer a unique cell-type-specific cell-to-cell interaction network in MS and identify potential biomarkers by comparative analysis of the brain and the blood transcriptomics. From a study design and methodology perspective, we suggest that the cell-type-specific interactome analysis is an important systems science frontier that might offer new insights on other neurodegenerative and brain disorders as well.
Elk-1 is a member of the ETS domain transcription factor superfamily that is phosphorylated upon mitogen-activated protein kinase (MAPK) pathway activation, which in turn regulated its interaction with partner protein serum response factor (SRF), leading to formation of a ternary complex with DNA. It has previously been reported that Elk-1 interacts with a mitotic kinase Aurora-A, although the mechanisms or the relevance of this interaction was unclear. Elk-1 was also reported to be phosphorylated by CDK5 on Thr417 residue. In this study, we show for the first time that this transcription factor interacts not only with Aurora-A but also with other mitotic kinases Aurora-B, Plk1, and Cdk1, and we define the interaction domain on Elk-1 to the first N-terminal 205 amino acids. We also describe putative phosphorylation sites of these mitotic kinases on Elk-1 and show that Elk-1 peptides containing these residues get phosphorylated by the mitotic kinases in in vitro kinase assays. We also perform bioinformatic analysis of mitotic phosphoproteomes and determine potential interaction partners for Elk-1 in Plk or Aurora phosphoproteomes. We propose that understanding the dynamic phosphorylation of Elk-1 by mitotic kinases is important and that it can present a novel target for anticancer strategies.
B cells have arisen as key in multiple sclerosis (MS) pathogenesis by the high efficacy of B cell depleting CD20 monoclonal antibodies and by the identification of Epstein-Barr virus (EBV) as a prerequisite factor. We previously demonstrated an expansion of memory and double negative (DN) B cells in the deep cervical lymph nodes (dcLNs) of newly diagnosed patients with MS (pwMS), with DN B cells showing a molecular signature consistent with lytic EBV infection. Effect of anti-CD20 therapies for pwMS require sustained administration, which led us to hyhenhesize that incomplete effects on the dcLNs, a natural site for lymphocyte priming towards the central nervous system (CNS), might be sustaining the pathology. Using single-cell transcriptomics and paired sampling, we characterized the effects of anti-CD20 therapies on dcLNs compared to circulation and to other therapies. We observed switched (SM) and unswitched (USM) memory B cells to be depleted uniquely by anti-CD20 in both dcLNs and circulation, whereas DN B cells of the dcLNs were not. Moreover, EBV lytic signature was retained in DN B cells during anti-CD20, and using clonal trajectory we saw that the DN B cells continued to contribute to the plasmablast differentiation within dcLNs. EBV targeting of expanded memory CD8 T cells, as well as CD8 T cell exhaustion, were retained during anti-CD20 therapy within the dcLNs. Our findings suggest a sustained, EBV-driven process in pwMS during anti-CD20 in the CNS-targeting priming dcLNs, with therapeutic implications to be investigated further. One Sentence Summary: Cervical lymph nodes show sustained, EBV-driven pathology in multiple sclerosis during anti-CD20 therapy unseen in peripheral blood.